Anti-CD20 Treatment of Autoimmune Hemolytic Anemia Refractory to Corticosteroids and Azathioprine: A Pediatric Case Report and Mini Review
Autoimmune hemolytic anemia (AIHA) is a relatively uncommon hematological entity in children and sometimes is characterized by a severe course requiring more than one line course therapy. Treatment decisions depend on the severity and chronicity of the anemia and the characteristics of the autoantib...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2018/8471073 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832558912302219264 |
|---|---|
| author | Alexandros Makis Zoi Kanta Dimitrios Kalogeropoulos Nikoloaos Chaliasos |
| author_facet | Alexandros Makis Zoi Kanta Dimitrios Kalogeropoulos Nikoloaos Chaliasos |
| author_sort | Alexandros Makis |
| collection | DOAJ |
| description | Autoimmune hemolytic anemia (AIHA) is a relatively uncommon hematological entity in children and sometimes is characterized by a severe course requiring more than one line course therapy. Treatment decisions depend on the severity and chronicity of the anemia and the characteristics of the autoantibodies. Immunosuppression with corticosteroids is the first-line treatment, especially in warm-reactive AIHA. Refractory cases are treated with immunosuppressive drugs, cytotoxic agents, androgens, or splenectomy, with various side effects and questionable efficacy. Another second-line option is rituximab, an anti-CD20 monoclonal antibody, which has been used as an off-label agent with encouraging results from small limited studies or case reports. Herein, we add our experience on the safety and clinical efficacy of rituximab by presenting the case of a boy with warm-type AIHA resistant to corticosteroids and azathioprine, successfully treated with rituximab. We also offer a review of the relevant literature. |
| format | Article |
| id | doaj-art-15d93430e7474bd6883d43ad8633bbab |
| institution | Kabale University |
| issn | 2090-6560 2090-6579 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-15d93430e7474bd6883d43ad8633bbab2025-02-03T01:31:11ZengWileyCase Reports in Hematology2090-65602090-65792018-01-01201810.1155/2018/84710738471073Anti-CD20 Treatment of Autoimmune Hemolytic Anemia Refractory to Corticosteroids and Azathioprine: A Pediatric Case Report and Mini ReviewAlexandros Makis0Zoi Kanta1Dimitrios Kalogeropoulos2Nikoloaos Chaliasos3Department of Pediatrics, University Hospital of Ioannina, Ioannina, GreeceDepartment of Pediatrics, University Hospital of Ioannina, Ioannina, GreeceDepartment of Pediatrics, University Hospital of Ioannina, Ioannina, GreeceDepartment of Pediatrics, University Hospital of Ioannina, Ioannina, GreeceAutoimmune hemolytic anemia (AIHA) is a relatively uncommon hematological entity in children and sometimes is characterized by a severe course requiring more than one line course therapy. Treatment decisions depend on the severity and chronicity of the anemia and the characteristics of the autoantibodies. Immunosuppression with corticosteroids is the first-line treatment, especially in warm-reactive AIHA. Refractory cases are treated with immunosuppressive drugs, cytotoxic agents, androgens, or splenectomy, with various side effects and questionable efficacy. Another second-line option is rituximab, an anti-CD20 monoclonal antibody, which has been used as an off-label agent with encouraging results from small limited studies or case reports. Herein, we add our experience on the safety and clinical efficacy of rituximab by presenting the case of a boy with warm-type AIHA resistant to corticosteroids and azathioprine, successfully treated with rituximab. We also offer a review of the relevant literature.http://dx.doi.org/10.1155/2018/8471073 |
| spellingShingle | Alexandros Makis Zoi Kanta Dimitrios Kalogeropoulos Nikoloaos Chaliasos Anti-CD20 Treatment of Autoimmune Hemolytic Anemia Refractory to Corticosteroids and Azathioprine: A Pediatric Case Report and Mini Review Case Reports in Hematology |
| title | Anti-CD20 Treatment of Autoimmune Hemolytic Anemia Refractory to Corticosteroids and Azathioprine: A Pediatric Case Report and Mini Review |
| title_full | Anti-CD20 Treatment of Autoimmune Hemolytic Anemia Refractory to Corticosteroids and Azathioprine: A Pediatric Case Report and Mini Review |
| title_fullStr | Anti-CD20 Treatment of Autoimmune Hemolytic Anemia Refractory to Corticosteroids and Azathioprine: A Pediatric Case Report and Mini Review |
| title_full_unstemmed | Anti-CD20 Treatment of Autoimmune Hemolytic Anemia Refractory to Corticosteroids and Azathioprine: A Pediatric Case Report and Mini Review |
| title_short | Anti-CD20 Treatment of Autoimmune Hemolytic Anemia Refractory to Corticosteroids and Azathioprine: A Pediatric Case Report and Mini Review |
| title_sort | anti cd20 treatment of autoimmune hemolytic anemia refractory to corticosteroids and azathioprine a pediatric case report and mini review |
| url | http://dx.doi.org/10.1155/2018/8471073 |
| work_keys_str_mv | AT alexandrosmakis anticd20treatmentofautoimmunehemolyticanemiarefractorytocorticosteroidsandazathioprineapediatriccasereportandminireview AT zoikanta anticd20treatmentofautoimmunehemolyticanemiarefractorytocorticosteroidsandazathioprineapediatriccasereportandminireview AT dimitrioskalogeropoulos anticd20treatmentofautoimmunehemolyticanemiarefractorytocorticosteroidsandazathioprineapediatriccasereportandminireview AT nikoloaoschaliasos anticd20treatmentofautoimmunehemolyticanemiarefractorytocorticosteroidsandazathioprineapediatriccasereportandminireview |